Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Yale Cancer Center · GlaxoSmithKline (United States) · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
582
total citations
- FWCI
- 38.88
- Percentile
- 100%
- References
- 28
Citations per year
Authors
9Topics & keywords
Topics
Keywords
- Medicine
- Mepolizumab
- Asthma
- Placebo
- Quality of life (healthcare)
- Physical therapy
- Internal medicine
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.